NASDAQ · LRMR
Larimar Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for LRMR: Nov 4, 2026
Larimar Therapeutics, Inc. Common Stock is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.35. The reported EPS for the same quarter last year was $-0.61.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.35 | $-0.34 | $-0.37 | 3 |
| Dec 2026 | $-0.37 | $-0.35 | $-0.40 | 3 |
| Mar 2027 | $-0.35 | $-0.27 | $-0.42 | 3 |
| Jun 2027 | $-0.35 | $-0.24 | $-0.43 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · MarketBeat · Zacks · RTTNews- BNK Invest · Oct 20, 12:24 PM EDTTuesday Sector Leaders: Biotechnology, DrugsIn trading on Tuesday, biotechnology shares were relative leaders, up on the day by about 4.2%. Leading the group were shares of Myriad Genetics, up about 37.5% and shares of Larimar Therapeutics up about 14.4% on the day. Also showing relative strength are drugs shares, up on
- MarketBeat · Oct 10, 10:35 AM EDT3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts AheadSmall-cap stocks tend to fly under the radar. Often in startup stages, these companies can lack analyst coverage, be overlooked by institutional investors, and be illiquid due to low average trading volume. But occasionally, some small caps present investment theses that are so
- Zacks · Oct 5, 8:35 AM EDTLarimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerThe heavy selling pressure might have exhausted for Larimar (LRMR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- RTTNews · Sep 30, 1:11 AM EDTLarimar Therapeutics Names John Harlow As President And COO(RTTNews) – Larimar Therapeutics, Inc. (LRMR), a clinical-stage biotechnology company, announced the appointment of John Harlow as President and Chief Operating Officer, effective September 29, 2026. He will report to Carole Ben-Maimon, Larimar's Chief Executive Officer.
- Zacks · Sep 14, 9:30 AM EDT5 Small Drug Stocks Poised to Benefit From a Biotech RecoveryINDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
- BNK Invest · Jul 9, 11:49 AM EDTThursday 7/9 Insider Buying Report: LRMR, EVMNBargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Today
- RTTNews · Jun 29, 9:20 AM EDTLarimar Submits First Module Of BLA For Nomlabofusp, Reports Positive Long-Term FA Data(RTTNews) – Larimar Therapeutics, Inc. (LRMR) on Monday said it has submitted the first module of its rolling Biologics License Application (BLA) to the Food and Drug Administration seeking accelerated approval of nomlabofusp for the treatment of Friedreich's ataxia (FA), a rare
- RTTNews · Jun 26, 11:38 PM EDTLarimar To Host Investor Event On Nomlabofusp Program On Monday, Stock Up(RTTNews) – Larimar Therapeutics, Inc. (LRMR), a clinical-stage biotechnology company focused on rare diseases, announced it will host an investor event to provide updates on its Nomlabofusp program for Friedreich's ataxia. The webcast is scheduled for Monday, June 29, 2026, at 7
- RTTNews · Jun 9, 10:44 PM EDTTop Biotech Gainers: RGNT Walks The Talk, ELOX Returns To Relevance, ALHC Rallies, LRMR On Watch(RTTNews) – Tuesday's top biotech gainers include Regentis, which provided an update on its single-step knee repair implant; Eloxx, after getting uplisted to the Nasdaq; Alignment Healthcare, following recent corporate disclosures, including restricted stock unit (RSU) grants to
- Fintel · May 27, 5:14 PM EDTJP Morgan Initiates Coverage of Larimar Therapeutics (LRMR) with Overweight RecommendationFintel reports that on May 27, 2026, JP Morgan initiated coverage of Larimar Therapeutics (NasdaqGM:LRMR) with a Overweight recommendation. Analyst Price Forecast Suggests 376.85% Upside
- Zacks · Mar 6, 10:26 AM ESTLRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?Larimar's stock jumps 55% in a month after the FDA grants breakthrough therapy status to its FA drug nomlabofusp and backs a potential accelerated path.
- RTTNews · Feb 26, 5:51 AM ESTLarimar Therapeutics Prices Upsized 20 Mln Public Offering At $5.00 Per Share, Stock Down(RTTNews) – Larimar Therapeutics, Inc. (LRMR), a clinical-stage biotechnology company developing treatments for rare diseases, Thursday priced its upsized underwritten public offering of 20 million shares of its common stock at $5 per share. The aggregate gross proceeds from this
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Larimar Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.